A41 Category · further specificity required Other sepsis
ICD-10-CM A41 identifies “Other sepsis” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 1: Certain infectious and parasitic diseases
Code-level instructions
Excludes 14
Excludes 213
- sepsis (due to) (in) actinomycotic (A42.7)
- sepsis (due to) (in) anthrax (A22.7)
- sepsis (due to) (in) candidal (B37.7)
- sepsis (due to) (in) Erysipelothrix (A26.7)
- sepsis (due to) (in) extraintestinal yersiniosis (A28.2)
- sepsis (due to) (in) gonococcal (A54.86)
- sepsis (due to) (in) herpesviral (B00.7)
- sepsis (due to) (in) listerial (A32.7)
- sepsis (due to) (in) melioidosis (A24.1)
- sepsis (due to) (in) meningococcal (A39.2-A39.4)
- sepsis (due to) (in) plague (A20.7)
- sepsis (due to) (in) tularemia (A21.7)
- toxic shock syndrome (A48.3)
Code first6
- , if applicable, postprocedural sepsis (T81.44-)
- sepsis due to central venous catheter (T80.211-)
- sepsis during labor (O75.3)
- sepsis following abortion, ectopic or molar pregnancy (O03.37, O03.87, O04.87, O07.37, O08.82)
- sepsis following immunization (T88.0-)
- sepsis following infusion, transfusion or therapeutic injection (T80.22-, T80.29-)
Inherited instructions
Chapters 1 · Certain infectious and parasitic diseases (A00-B99)
Includes1
diseases generally recognized as communicable or transmissible
Excludes 25
- carrier or suspected carrier of infectious disease (Z22.-)
- certain localized infections - see body system-related chapters
- infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium (O98.-)
- infectious and parasitic diseases specific to the perinatal period (P35-P39)
- influenza and other acute respiratory infections (J00-J22)
Use additional code1
code to identify resistance to antimicrobial drugs (Z16.-)
More specific codes
A41.0Sepsis due to Staphylococcus aureusCategory · further specificity requiredA41.1Sepsis due to other specified staphylococcusBillable / specificA41.2Sepsis due to unspecified staphylococcusBillable / specificA41.3Sepsis due to Hemophilus influenzaeBillable / specificA41.4Sepsis due to anaerobesBillable / specificA41.5Sepsis due to other Gram-negative organismsCategory · further specificity requiredA41.8Other specified sepsisCategory · further specificity requiredA41.9Sepsis, unspecified organismBillable / specificOfficial index references
Official index references (1)
Disorder(of) (1)
- Disorder(of) › glomerular(in) › sepsis NECDisease index
References from other codes (7)
Code first · sepsis (A41.-)
Use additional code · sepsis (A40, A41.-)
Use additional code · sepsis (A40.-, A41.-)
Use additional code · sepsis (A40.-, A41.-)
Use additional code · sepsis (A40.-, A41.-)
Use additional code · sepsis (A40.-, A41.-)
Use additional code · sepsis (A40.-, A41.-)
History
Code history
Latest recorded change · FY2027
Effective from
- Inherited rules changed
Other sepsis
Category — select a more specific code
CDC/NCHS · FY2027All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | Code-level rules changed |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | Code-level rules changed |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | Inherited rules changed |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.